---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000011"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:40:40.487549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q4 GAAP loss $0.02 (emraclidine impairment), adj. EPS $2.16; FY rev $56.3B, 2025 adj. EPS guide $12.12-12.32

## Summary
- Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).
- Q4 GAAP diluted loss per share $0.02 (includes $3.5B impairment for emraclidine); adjusted diluted EPS $2.16.
- Global Skyrizi revenue $3.778B (+57.7%) in Q4; Rinvoq revenue $1.834B (+46.2%); Humira revenue -49.1% to $1.682B.
- 2025 adjusted EPS guidance $12.12-$12.32; raises 2027 Skyrizi+Rinvoq revenue outlook to >$31B.
- Full-year immunology revenue $26.682B (+2.1%); neuroscience $8.999B (+16.6%); aesthetics $5.176B (-2.2%).

## SEC filing metadata
- accession: 0001551152-25-000011
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/0001551152-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/abbv-20250131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000011
- JSON: https://secwatch.observer/filing/0001551152-25-000011.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.